<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00071968</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000331979</org_study_id>
    <secondary_id>UCLA-0306091</secondary_id>
    <secondary_id>WYETH-C-3066A1-132-US</secondary_id>
    <nct_id>NCT00071968</nct_id>
  </id_info>
  <brief_title>Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse</brief_title>
  <official_title>An Open-Label Study Of Exploratory Pharmacogenomics And Pharmacologic Effects Of Neoadjuvant Oral CCI-779 In Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have A High Risk Of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Giving CCI-779 before surgery may shrink the&#xD;
      tumor so that it can be removed.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well CCI-779 works in treating&#xD;
      patients who are undergoing radical prostatectomy for newly diagnosed prostate cancer at high&#xD;
      risk of relapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the effects of oral CCI-779 on changes in the phosphorylation state of&#xD;
           proteins in the mammalian target of rapamycin (mTOR) signaling pathway in the tumor&#xD;
           tissue of patients with newly diagnosed prostate cancer undergoing radical&#xD;
           prostatectomy.&#xD;
&#xD;
        -  Determine the effects of this drug on changes in p70S6 kinase activity, phosphorylation&#xD;
           state of mTOR pathway proteins, and on global and targeted gene expression patterns in&#xD;
           the peripheral blood mononuclear cells (PBMCs) of these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effects of this drug on global and targeted gene expression patterns in&#xD;
           these patients.&#xD;
&#xD;
        -  Identify pharmacodynamic/pharmacogenomic surrogate markers of this drug in both tumor&#xD;
           tissue and PBMCs and determine if blood may be used as a surrogate tissue source for&#xD;
           biomarkers of drug activity in the tumor in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the potential antitumor effects of this drug in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Correlate phosphatase and tensin homolog (PTEN) gene status with the&#xD;
           pharmacodynamic/pharmacogenomic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the effects of this drug on changes in protein expression patterns in the&#xD;
           plasma of these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of&#xD;
      3 treatment arms. Patients randomized to arm III are stratified according to tumor expression&#xD;
      of phosphatase and tensin homolog (PTEN) gene mutations (negative vs positive).&#xD;
&#xD;
        -  Arm I: Patients receive oral CCI-779 once daily for a total of 8 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive a higher dose of CCI-779 as in arm I.&#xD;
&#xD;
        -  Arm III: Patients receive a higher dose (higher than arm II) of CCI-779 as in arm I.&#xD;
&#xD;
      Approximately 24-48 hours after the last dose of CCI-779, patients in all arms undergo&#xD;
      radical prostatectomy.&#xD;
&#xD;
      Patients are followed on day 7-10 and then at 4 weeks after study completion.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients (5 each for arms I and II and 30 for arm III) will&#xD;
      be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phosphorylation state of proteins</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>p70S6 kinase activity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphorylation state of mTOR pathway proteins</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Global and targeted gene expression patterns in peripheral blood mononuclear cells</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global and targeted gene expression patterns</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics and pharmacogenomic surrogate markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of phosphatase and tensin homolog gene status with pharmacodynamic and pharmacogenomic effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein expression patterns in the plasma</measure>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Diagnosis based on a minimum of 6 core biopsy samples&#xD;
&#xD;
               -  Clinically confirmed organ-confined disease&#xD;
&#xD;
          -  Candidate for radical prostatectomy&#xD;
&#xD;
          -  No evidence of metastatic disease by CT scan and bone scan&#xD;
&#xD;
          -  High risk of relapse based on either of the following criteria:&#xD;
&#xD;
               -  Any one of the following:&#xD;
&#xD;
                    -  Stage T2C or higher&#xD;
&#xD;
                    -  Gleason score greater than 7&#xD;
&#xD;
                    -  Prostate-specific antigen (PSA) greater than 20 ng/mL OR&#xD;
&#xD;
               -  Any two of the following:&#xD;
&#xD;
                    -  Gleason score at least 7&#xD;
&#xD;
                    -  PSA 10-20 ng/mL&#xD;
&#xD;
                    -  Greater than 50% of total biopsy cores with cancer involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No active bleeding&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No acute or chronic hepatitis B&#xD;
&#xD;
               -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  No acute or chronic hepatitis C&#xD;
&#xD;
               -  No antibodies to hepatitis C&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  No ongoing urinary tract infection necessitating rapid or emergent surgical resection&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No life-threatening ventricular arrhythmia requiring ongoing maintenance therapy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No known pulmonary hypertension&#xD;
&#xD;
          -  No pneumonitis&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 weeks after study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other severe immunocompromised states&#xD;
&#xD;
          -  No active infection requiring antibiotic therapy&#xD;
&#xD;
          -  No serious concurrent illness&#xD;
&#xD;
          -  No other major illness that would substantially increase the risk associated with&#xD;
             study participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell or squamous cell skin&#xD;
             cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 3 weeks since prior IV corticosteroids&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
          -  No prior or concurrent hormonal therapy for underlying malignancy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior or concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 3 months since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 1 month since prior experimental drugs&#xD;
&#xD;
          -  More than 3 weeks since prior immunosuppressive agents&#xD;
&#xD;
          -  No concurrent immunosuppressive therapies&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsants (e.g., phenobarbital, phenytoin, or&#xD;
             carbamazepine)&#xD;
&#xD;
          -  No concurrent ketoconazole, diltiazem, rifampin, terfenadine, cisapride, astemizole,&#xD;
             pimozide, or Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No concurrent grapefruit or grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Sawyers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1738</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Thomas G, Speicher L, Reiter R, et al.: Demonstration that temsirolimus preferentially inhibits the mTOR pathway in the tumors of prostate cancer patients with PTEN deficiencies. [Abstract] Clin Cancer Res 11 (Suppl 24): A-C131, 2005.</citation>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

